69038-81-9

Usage

Uses

Used in Pharmaceutical Research:
2-Ethoxycinnamic acid is used as a pharmaceutical intermediate for its anti-inflammatory, anti-tumor, and antioxidant properties. It is valued for its potential therapeutic applications in treating various conditions due to these beneficial effects.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Ethoxycinnamic acid is utilized as a key building block for the creation of more complex organic compounds, leveraging its reactive sites for further chemical transformations.
Used in UV Protection:
2-Ethoxycinnamic acid is used as a UV-absorbing agent in various products, such as sunscreens and other cosmetic formulations, to protect the skin from harmful ultraviolet radiation.
Used in Fragrance and Flavoring Production:
2-Ethoxycinnamic acid is employed as a component in the production of fragrances and flavorings, contributing to the unique scents and tastes in a variety of consumer products.
Used in Polymer Material Manufacturing:
In the polymer industry, 2-Ethoxycinnamic acid is used in the manufacturing of polymer materials, where its chemical properties can influence the material's characteristics, such as stability and reactivity.
Each application of 2-Ethoxycinnamic acid leverages its unique chemical structure and properties, making it a versatile and valuable compound in a wide array of industries.

InChI:InChI=1/C11H12O3/c1-2-14-10-6-4-3-5-9(10)7-8-11(12)13/h3-8H,2H2,1H3,(H,12,13)/b8-7+

Upstream product

• 110-86-1 pyridine 
• 141-82-2 malonic acid 
• 613-69-4 2-ethoxylbenzaldehyde 
• 64-19-7 acetic acid 

Downstream Products

• 84050-32-8 (E)-1-[4-(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-piperazin-1-yl]-3-(2-ethoxy-phenyl)-propenone; hydrochloride 
• 70842-56-7 1-[3-(2-ethoxy-phenyl)-acryloyl]-piperazine 
• 1429518-86-4 8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-6(5H)-thione 
• 599151-35-6 8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6-(5H)-one 
• 1373209-39-2 (-)-(S)-8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one 
• 1373209-40-5 (+)-(R)-8-(2-ethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-6(5H)-one 
• 1429518-81-9 5-(2-ethoxyphenyl)-4,5-dihydro-[1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline 

Relevant academic research and scientific papers

Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP

CGRP, known as the most potent vasodilator substance, plays an important role in hypertension initiation and development. TRPV1 and TRPA1 are critical in promoting the synthesis and release of CGRP, thereby regulating the cardiovascular tone. Rutaecarpine exhibits potent vasodilator and hypertensive effects by stimulating CGRP synthesis and release via activation of TRPV1. And NO has been shown to react with H2S in vivo to form HNO, thereby activating HNO-TRPA1-CGRP pathway. Inspired by combination therapy, 11 rutaecarpine-furoxan hybrids were designed, synthesized and evaluated. The results demonstrated that most hybrids exerted comparable or improved vasodilator activities. Among which, 13a is the most potent both ex vivo (EC50 = 13.1 nM) and in vivo. Mechanistic studies revealed that the vasodilator and anti-hypertensive effects of the hybrids might involve the promotion of CGRP release via dual activation of TRPV1 and TRPA1. This work suggests that dual-targeted hybrids might be an effective and promising approach to discover and develop novel anti-hypertensive drugs.

Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells

A series of novel 2-phenylaminopyrimidine (PAP) derivatives structurally related to STI-571 were designed and synthesized. The abilities of these compounds to inhibit proliferation were tested in human chronic myeloid leukemia K562 cells. (E)-3-(2-bromophenyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)phenyl]acrylamide( 12d) was the most effective cell growth inhibitor and was 3-fold more potent than STI-571.